Lead Sponsor

Yamagata University

Age

20 - 80 years

Sex

ALL

Healthy Volunteers

No

•Age: 20-80 years old, both inclusive
•ECOG performance status of 0, 1, or 2
•MSKCC risk of favorable or intermediate
•Histologically confirmed renal cell carcinoma
•No ischemic heart disease
•Laboratory findings meet the following criteria:
•1. Respiratory function: %VC, 80% and FEV1.0,70%
•2. Hematology: white blood cell count4,000/mm3, platelet count100,000/mm3
•3. Clinical chemistry: GOT and GPT within the normal range of each medical institution; total bilirubin \<1.5 x ULN
•4. Serum creatinin \<2.0mg/dl, blood urea nitrogen (BUN) \<25mg/dl
•5. Echocardiographic estimation of left ventricular ejection fraction is higher than the lower limit of reference range of each medical institution.

•History of any other malignancy
•Central nervous system metastases. However, patients who remain asymptomatic, have no new or enlarging lesion in the CNS within 6 months of enrollment in this study, and require no corticosteroids may be enrolled.
•History of cardiac infarction, unstable angina, congestive heart failure, or symptomatic peripheral vascular disease within 12 months of enrollment
•History of cerebrovascular disorder including transient ischemic attack (TIA)
•Pregnancy or possible pregnancy at any time during the study
•Ongoing grade 2 adverse event prior treatment
•Prior treatment with any anticancer therapy including cytokine therapy such as interferon-alpha and interleukin-2
•Prior treatment with mTOR inhibitor
•Prior treatment with sunitinib or sorafenib
•Treatment with an test drug in a clinical research within 4 weeks of enrollment in this study

Related studies

NCT06863311 · Advanced Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma, and more

NCT06500455 · Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, and more

NCT04693377 · Castration-Resistant Prostate Carcinoma, Metastatic Colorectal Carcinoma, and more

NCT07123090 · Metastatic Renal Cell Carcinoma, Metastatic Renal Cancer, and more

NCT06391099 · Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Cutaneous Melanoma, and more

Comparison of Sequential Therapies With Sunitinib and Sorafenib in Advanced Renal Cell Carcinoma